eGenesis
received FDA IND clearance for EGEN-2784, its genetically engineered porcine kidney, to begin a formal clinical trial for end-stage kidney disease, building on an ongoing expanded-access compassionate-use program with reported patient updates.
- Country
- United States
xenotransplant
kidney
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Xenotransplantation | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.